Accelerating Clinically Differentiated Treg & Treg-Modulating Therapies to Deliver Durable Immune Tolerance in Autoimmune, Inflammatory, & Neurodegenerative Disease
Following the first FDA approval of a Treg-based therapy with Orca Bio's Tregzi, growing clinical validation across both cell-based and modulatory approaches, and increasing recognition of immune tolerance as a potentially safer strategy for treating autoimmune disease, the conversation is rapidly shifting from proving the biology to demonstrating clinical differentiation, manufacturing scalability, and commercial viability.
Against this backdrop, the 9th Treg-Directed Therapies Summit returns as the industry's longest-running and most dedicated forum focused exclusively on advancing regulatory T-cell therapies. Bringing together biopharma, academic, and investment leaders driving the field forward, the summit provides a unique opportunity to benchmark emerging clinical data and evaluate the strategies best positioned to deliver durable immune tolerance across immune disease.
The 2027 program focuses on the key clinical and operational challenges shaping the next generation of Treg-directed therapies, from translating promising biology into differentiated clinical outcomes to building scalable platforms capable of long-term success. Alongside two new preconference workshops dedicated to advancing Treg biology and analytical development, potency assays and characterization, attendees will gain practical insights, exchange lessons learned, and connect with the stakeholders driving the future of immune tolerance.
Understanding and manipulating Tregs for the development of immunotherapy in autoimmune diseases, transplantation and cancer hold great promise for these patients. This summit is an ideal platform to learn and exchange the updated information and knowledge in the field.
Wanjun Chen, Senior Investigator, NIH
This meeting combined leading professionals in the Treg field and provided the opportunity to communicate on what is happening in the field and take key learnings back to the team.
Hong Jiang, Chief Scientific Officer, Avotres
I loved the content and particularly enjoyed that the presentations that covered Treg related therapies from early development to manufacturing and clinical development.
Zengli Guo, Associate Director, AstraZeneca
New for 2027: World Immune Tolerance Week
For the very first time, the 9th Treg-Directed Therapies Summit is becoming part of World Immune Tolerance Week alongside the 10th Antigen-Specific Immune Tolerance Summit and the 2nd Immune Resetting: B-Cell Mediated & Beyond Summit to bring together the full autoimmune and immunology disease community. While each summit retains its own scientific focus, expert speaker faculty, and community, attendees will gain access to all three meetings, enabling cross-disciplinary learning, richer networking, and collaboration across antigen-specific therapies, Treg approaches, B-cell modulation, and broader immune resetting strategies.
Expand the Application of Treg Therapies into a Clinical Reality
Advancing Transformative Therapies to Reset Autoimmune Diseases
Accelerating Curative Therapies for Autoimmune Diseases
Attending Companies Include
Official 2026 Partners
Explore Related Events
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.